Acorda Therapeutics, Inc. short interest in 2021
In 2021, Acorda Therapeutics, Inc.'s disclosed short interest ran from 11.26% of shares outstanding on 15 Mar 2021 to 8.40% on 30 Nov 2021, a change of -2.86 percentage points. The year's high was 15.10% on 28 May 2021 and its low 3.80% on 15 Oct 2021, averaging 9.21% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.15 days on 28 May 2021. Full history: Acorda Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2021 in figures
- Start of year
- 11.26% (15 Mar 2021)
- End of year
- 8.40% (30 Nov 2021)
- Change
- -2.86 pp
- High
- 15.10% (28 May 2021)
- Low
- 3.80% (15 Oct 2021)
- Average
- 9.21%
- Highest days to cover
- 11.15 (28 May 2021)
- SEC filings marked
- 9
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Mar 2021 | 11.26% | 3.51 | results (8-K), results (8-K) |
| 31 Mar 2021 | 12.23% | 7.66 | 10-K filed |
| 15 Apr 2021 | 13.09% | 7.39 | |
| 30 Apr 2021 | 12.58% | 8.65 | |
| 14 May 2021 | 12.75% | 9.10 | results (8-K), 10-Q filed |
| 28 May 2021 | 15.10% | 11.15 | |
| 15 Jun 2021 | 8.37% | 1.82 | |
| 30 Jun 2021 | 7.12% | 1.72 | |
| 15 Jul 2021 | 6.27% | 4.97 | |
| 30 Jul 2021 | 12.52% | 1.00 | |
| 13 Aug 2021 | 12.67% | 3.70 | results (8-K), 10-Q filed |
| 31 Aug 2021 | 8.44% | 4.48 | |
| 15 Sep 2021 | 6.81% | 4.98 | |
| 30 Sep 2021 | 5.13% | 5.14 | |
| 15 Oct 2021 | 3.80% | 4.03 | |
| 29 Oct 2021 | 3.91% | 4.84 | |
| 15 Nov 2021 | 5.24% | 3.31 | results (8-K), 10-Q filed |
| 30 Nov 2021 | 8.40% | 3.84 |
See also: Acorda Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.